Evaluating Low-T Claims: How Testosterone Deficiency Is Actually Diagnosed in the Evidence

A defensible diagnosis of testosterone deficiency rests on two things held together, not one number in isolation. The 2018 Endocrine Society clinical practice guideline recommends diagnosing hypogonadism only in men who have both symptoms and signs of testosterone deficiency and unequivocally, consistently low serum testosterone. Consistency matters because roughly 30 percent of men whose first reading falls in the hypogonadal range test normal on repeat measurement. A single low value drawn at a convenient hour, absent symptoms, does not meet the standard that the evidence describes.

That gap between the evidence and the pitch is where "Low-T" marketing lives. This article explains what a rigorous evaluation looks like so you can read a claim critically. It is educational, not medical advice, and no part of it is a recommendation to test or treat.

What the guideline actually asks for

The Endocrine Society guideline sets out a deliberate sequence rather than a shortcut. The first step is a fasting morning measurement of total testosterone using an accurate, reliable assay. Timing is not arbitrary. Testosterone follows a daily rhythm, peaking in the morning, so an afternoon draw can read low in a man whose morning levels are normal. Food intake and acute illness can push values down as well, which is why the guideline specifies fasting and morning conditions.

The second step is confirmation. If the first morning value is low, the guideline recommends repeating the fasting morning measurement before making any diagnosis. This is not bureaucratic caution. Testosterone varies substantially within the same person from day to day, and that 30 percent reversion rate on retesting is the reason a one-time result cannot stand alone. A rigorous workup treats a single low number as a question, not an answer.

The guideline also anchors the biochemistry to a harmonized reference range derived from healthy young men, with the middle 95 percent of that population falling between roughly 264 and 916 ng/dL. Ranges depend on the assay and the laboratory, so a number only means something in the context of how it was measured.

The role of symptoms

Symptoms are not decoration on top of a lab value. In the guideline's framing they are half of the diagnosis. The relevant symptoms and signs, such as reduced libido, loss of morning erections, low energy, or diminished muscle mass, overlap heavily with sleep deprivation, depression, thyroid disease, medication effects, and ordinary aging. That overlap is exactly why a low number without a matching clinical picture, or a compelling symptom story without confirmed low testosterone, falls short. The evidence asks for both to point the same way.

The borderline zone and SHBG

Total testosterone can mislead when sex hormone-binding globulin is abnormal, as it can be with obesity, diabetes, thyroid disease, or aging. In men whose total testosterone sits near the lower limit of normal, or who have a condition that alters this binding protein, the guideline recommends estimating free testosterone by equilibrium dialysis or a validated calculation. The point is that a borderline total value calls for a more careful measurement, not a faster prescription.

The marketing shortcut, and why it fails the test

The direct-to-consumer version typically compresses this whole sequence. A questionnaire heavy on nonspecific complaints, a single convenient blood draw, and a same-visit conclusion can turn a normal-variant afternoon dip into a diagnosis. Each shortcut removes one of the guideline's safeguards: the morning timing that controls for circadian rhythm, the fasting condition, the confirmatory second draw that catches the 30 percent who revert, and the requirement that symptoms and biochemistry agree. What is left is a number stripped of the context that gives it meaning.

Reading a claim critically means asking a few questions. Was the sample drawn in the morning, fasting? Was a low result confirmed on a separate day? Do documented symptoms actually match the biochemistry? Was the reference range from the reporting laboratory, or a generic cutoff? Those questions map directly onto what the evidence requires.

Why the 2025 label change is not a green light

In February 2025 the FDA announced class-wide labeling changes for testosterone products. Two changes drew attention. The agency removed the boxed-warning language about increased cardiovascular risk and added a summary of the TRAVERSE trial, a randomized study of more than 5,000 middle-aged and older men with hypogonadism and elevated cardiovascular risk, published in the New England Journal of Medicine in 2023, which found testosterone therapy did not raise the rate of major adverse cardiac events compared with placebo. That same trial reported a higher rate of nonfatal arrhythmias, including atrial fibrillation, and the FDA added blood-pressure warnings drawn from required post-market studies. So the update tightened one caution while relaxing another.

Precision about what the label now says versus what it is assumed to mean is the whole point here. Removing cardiovascular language from a boxed warning is a statement that the earlier warning was not supported by the trial evidence in the studied population. It is not an endorsement, a safety all-clear, or a suggestion that more men should be treated. The label still carries a Limitation of Use for age-related hypogonadism, and the products remain indicated only for men with testosterone deficiency due to a diagnosed medical condition, not for low readings attributed to aging alone. The diagnostic bar the Endocrine Society describes did not move because a warning was edited. If anything, the tightened blood-pressure language and the arrhythmia signal are reminders that any decision to treat belongs to an individual and a clinician weighing that person's specifics, not to a marketing funnel.

The takeaway

The distance between a rigorous diagnosis and a marketing conclusion is measurable: two mornings versus one afternoon, symptoms that match the biochemistry versus a checklist, a confirmed result versus a single number. When you encounter a Low-T claim, the useful move is not to accept or reject it on instinct but to check it against the sequence the evidence lays out. A number is a starting point for a question. The diagnosis is what survives careful repetition.